Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Researchers investigate oral cancer, periodontal disease relationship

Today during the 88th General Session & Exhibition of the International Association for Dental Research, in Barcelona, Spain, presenting author J. Meyle, Justus Liebig University, Giessen, Germany, will present an abstract titled "P. gingivalis Infection and Immune Evasion of Oral Carcinomas."

14 Jul 2010

Vanderbilt Medical Center treats first patient in Galil Medical's new TRACE renal registry

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry.

12 Jul 2010

Early knowledge of HCC response to TACE determines treatment success: Research article

Early knowledge of hepatocellular carcinoma response to transcatheter arterial chemoembolization is crucial for determining treatment success, timing of repeat treatment, and patient prognosis. Currently, magnetic resonance imaging is used 1-3 mo after treatment to evaluate anatomical tumor response, based upon changes in tumor size and contrast-agent enhancement. Alternatively, diffusion-weighted imaging can be used as a functional imaging technique to depict thermally induced motion of water molecules.

9 Jul 2010

SurModics licenses biodegradable polymer implant technology to Clinuvel

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has entered into a license agreement with Clinuvel Pharmaceuticals Limited of Melbourne, Australia. Under the agreement, the Company's SurModics Pharmaceuticals unit has licensed certain of its biodegradable polymer implant technology to Clinuvel for the treatment of sun-induced skin disorders. Terms of the agreement were not disclosed.

8 Jul 2010

Report investigates clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

8 Jul 2010

MicroRNAs accurately identify four histological types of renal tumors: Study

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics.

7 Jul 2010

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo Pharmaceuticals today announced the successful completion of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc..

3 Jul 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in the liver and is a pandemic over the globe especially in the developed countries, based on a high calorie diet and sedentary life style. As in the other types of chronic hepatitis, collagen fibers continuously accumulate in the liver through the course of NASH toward cirrhosis and hepatocellular carcinoma development.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.

28 Jun 2010

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Cancer Research UK scientists have discovered certain ovarian tumour cells that are resistant to chemotherapy can survive a first round of treatment and go on to "re-grow" the cancer. This could help explain why the disease can be difficult to treat, according to new research published in Oncogene today (Monday).

28 Jun 2010

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zila, leader in the prevention and detection of oral diseases, today introduced an angled exam mirror as part of the ViziLite Plus oral lesion identification and marking system. The autoclavable mirror attaches to the top of the ViziLite Plus lightstick retractor, enhancing dental professionals' ability to see oral lesions during a comprehensive oral cancer screening procedure.

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

Today, world renowned experts have assembled in Dubrovnik, Croatia to discuss the latest trends in treatment and cutting edge research in diagnostic techniques that will shape the future management of hepatocellular carcinoma - the third most common cause of cancer-related death globally, and a leading cause of death among patients with liver cirrhosis.

28 Jun 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

25 Jun 2010

Carcinoma News and Research

Further Reading

Researchers investigate oral cancer, periodontal disease relationship

Vanderbilt Medical Center treats first patient in Galil Medical's new TRACE renal registry

Early knowledge of HCC response to TACE determines treatment success: Research article

SurModics licenses biodegradable polymer implant technology to Clinuvel

Report investigates clear cell ICC

MicroRNAs accurately identify four histological types of renal tumors: Study

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Endo responds to FDA Complete Response letter for FORTESTA NDA

Study investigates efficacy of SWV measurement in evaluation of NASH pathophysiology using ultrasound

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

ADVANCE study provides new insights into the management of SHPT in CKD patients

Experts to discuss latest trends in treatments, diagnostic techniques for managing HCC

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News